한글목차

세계의 위운동 장애 치료제 시장은 2024년 547억 달러에 달했고, 2033년에는 904억 1,000만 달러에 이를 것으로 예측되며, 예측 기간(2025-2033년) 중 CAGR 5.0%로 성장할 전망입니다.

위운동 장애는 소화관(GI)을 통한 음식의 정상적인 이동에 영향을 미치며 메스꺼움, 구토, 복부 팽만감, 변비, 복통 등 다양한 증상을 일으키는 상태를 말합니다. 이러한 질병은 신경 손상, 구조 이상, 위장관에 영향을 미치는 감염과 같은 다양한 원인으로 인해 발생합니다.

일반적인 예로는 위 배출 지연을 특징으로 하는 위 마비나, 명확한 운동 기능 장애를 수반하지 않는 상복부의 불쾌감을 수반하는 기능성 소화불량 등이 있습니다. 이러한 질병은 복잡하기 때문에 환자의 QOL에 심각한 영향을 미치는 경우가 많으며 효과적인 관리 전략이 필요합니다. 위장운동촉진제(메토클로프라미드, 돈페리돈 등)와 같은 약물은 위 배출을 촉진하고 메스꺼움을 완화하기 위해 일반적으로 처방됩니다.

시장 역학:

촉진요인과 억제요인

위운동 장애의 유병률 증가

위운동 장애의 유병률 증가는 위운동 장애 치료제 시장을 크게 견인할 것으로 보입니다. 위부전 마비와 기능성 소화불량와 같은 질병의 환자 수가 증가함에 따라 효과적인 치료에 대한 수요도 증가하고 있습니다. 예를 들어, 2023년 국립위생연구소의 보고에 따르면, 기능성 소화불량는 인구의 20% 이상이 병을 앓는 가장 흔한 기능성 위장 장애 중 하나라고 말합니다.

중증 환자에서 위장관 운동 장애의 발생률은 약 50%에서 80%입니다. 이러한 환자 수 증가는 새로운 치료 옵션의 긴급한 필요성을 돋보이게 할 뿐만 아니라 제약 회사의 연구 개발에 투자를 촉진하여 위운동 장애 치료제 시장을 확대하고 있습니다. 따라서, 상기 요인이 예측 기간 동안 시장 성장을 가속할 것으로 예상됩니다.

제한된 치료제

위운동 장애의 치료제 옵션이 제한되어 있다는 것은 시장 성장을 크게 저해할 수 있습니다. 효과적이고 다양한 치료 옵션이 없기 때문에 환자의 요구가 충족되지 않아 효과가 부족하거나 부작용이 심각한 기존 약물에 의존합니다. 게다가 이러한 질병의 근본적인 메커니즘이 불분명하기 때문에 약물 개발이 복잡하다는 것은 새로운 치료법의 도입을 더욱 제한하고 궁극적으로 이 분야 시장 확대와 기술 혁신을 저해하고 있습니다.

목차

제1장 조사 방법과 조사 범위

제2장 정의와 개요

제3장 주요 요약

제4장 시장 역학

• 영향요인
  • 성장 촉진요인
    • 위운동 장애의 유병률 증가
  • 억제요인
    • 한정된 치료제
  • 기회
  • 영향 분석

제5장 산업 분석

• Porter's Five Forces 분석
• 공급망 분석
• 가격 분석
• 특허 분석
• 규제 분석
• SWOT 분석
• 미충족 요구

제6장 약제 유형별

• 소화관 운동 촉진제
• 부교감 신경 자극제
• 오피오이드 길항제
• 설사 방지
• 제토약
• 항생제
• 기타

제7장 질환 유형별

• 아칼라시아
• 식도 경련
• 속쓰림 또는 위식도 역류증(GERD)
• 위부전 마비
• 과민성 장 증후군(IBS)
• 편실금
• 장 가성 폐색
• 기타

제8장 유통 채널별

• 병원 약국
• 온라인 약국
• 소매 약국

제9장 지역별

• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 스페인
  • 이탈리아
  • 기타 유럽
• 남미
  • 브라질
  • 아르헨티나
  • 기타 남미
• 아시아태평양
  • 중국
  • 인도
  • 일본
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카

제10장 경쟁 구도

• 경쟁 시나리오
• 시황·점유율 분석
• M&A 분석

제11장 기업 프로파일

• Pfizer Inc.
  • 기업 개요
  • 제품 포트폴리오
    • 제품 설명
    • 제품의 주요 실적 평가 지표(KPI)
    • 과거 및 예측의 제품 판매
    • 제품 판매량
  • 재무 개요
    • 회사 수익
    • 지역별 수익분배
    • 수익 예측
  • 주요 발전
    • 합병과 인수
    • 주요 제품 개발 활동
    • 규제 당국의 승인 등
  • SWOT 분석
• Eisai Co., Ltd.
• Mallinckrodt
• Salvus Pharma
• Atmo Biosciences
• AdvaCare Pharma
• Avenacy
• VAIKUNTH CHEMICALS PVT. LTD.
• Healthy Inc
• Bhumi Pharmaceuticals
• Processa Pharmaceuticals, Inc.
  • 파이프라인 제품 설명
  • 제품의 주요 실적 평가 지표(KPI)
  • 주요 활동
  • 시장 진입의 타임라인
  • 제품 보급률
  • 매출 예측과 예측
• Vanda Pharmaceuticals Inc.
• Renexxion Ireland Limited
• Aclipse Therapeutics
• 각 시장 진출기업에 대해서도 유사한 데이터가 제공됩니다.

제12장 부록

영문목차

The global gastric motility disorder drugs market reached US$ 54.7 billion in 2024 and is expected to reach US$ 90.41 billion by 2033, growing at a CAGR of 5.0% during the forecast period 2025-2033.

Gastric motility disorders refer to conditions that affect the normal movement of food through the gastrointestinal (GI) tract, leading to a range of symptoms such as nausea, vomiting, bloating, constipation, and abdominal pain. These disorders can arise from various causes, including nerve damage, structural abnormalities, or infections affecting the GI tract.

Common examples include gastroparesis, characterized by delayed gastric emptying, and functional dyspepsia, which involves discomfort in the upper abdomen without clear motor dysfunction. The complexity of these disorders often results in significant impacts on patients' quality of life, necessitating effective management strategies. Medications such as prokinetic agents (e.g., metoclopramide and domperidone) are commonly prescribed to enhance gastric emptying and alleviate nausea.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Gastric Motility Disorders

The increasing prevalence of gastric motility disorders is expected to significantly drive the gastric motility disorder drugs market. As the number of individuals with conditions such as gastroparesis and functional dyspepsia increases, the demand for effective treatments rises correspondingly. For instance, according to the report by the National Institute of Health in 2023, it was stated that functional dyspepsia is one of the most prevalent functional gastrointestinal disorders that affects over 20% of the population.

The occurrence of GI motility disorders approximates 50-80% in the critically ill patients. This growing patient population not only highlights the urgent need for new therapeutic options but also encourages pharmaceutical companies to invest in research and development, thereby expanding the market for gastric motility disorder drugs. Thus, the above factors are expected to drive the market growth during the forecast period.

Limited Drugs for Treatment

Limited drug options for treating gastric motility disorders can significantly hinder market growth. The lack of effective and diverse treatment alternatives leads to unmet patient needs, resulting in a reliance on existing medications that may have inadequate efficacy or severe side effects. Additionally, the complexity of drug development due to unclear underlying mechanisms of these disorders further restricts the introduction of new therapies, ultimately stifling market expansion and innovation in this sector.

Segment Analysis

The global gastric motility disorder drugs market is segmented based on drug type, disorder type, distribution channel, and region.

Drug Type:

Prokinetic agents segment is expected to dominate the global gastric motility disorder drugs market share

The prokinetic agents segment is poised to dominate the gastric motility disorder drugs market. This dominance is attributed to their effectiveness in alleviating various symptoms associated with gastroparesis by enhancing gastrointestinal motility and promoting gastric emptying. Prokinetic agents, such as metoclopramide and domperidone, are widely recognized for their ability to improve symptoms like nausea and bloating, making them essential in the management of gastric motility disorders.

With the growing demand for these drugs, companies are innovatively introducing these solutions to treat various gastric motility disorders. For instance, in September 2024, Avenacy launched Metoclopramide Injection, USP in the United States as a therapeutic generic equivalent for Reglan as approved by the U.S. Food and Drug Administration. Metoclopramide Injection, USP is indicated for the relief of symptoms associated with diabetic gastroparesis. Thus, the above factors are expected to hold the segment in the dominant position.

Geographical Analysis

North America is expected to hold a significant position in the global Gastric Motility Disorder Drugs market share

North America holds a major portion of the gastric motility disorder drugs market and is expected to dominate the market during the forecast period. This dominance is driven by several factors, including a high prevalence of gastric motility disorders, and significant investments in pharmaceutical research and development. The presence of major drug manufacturers in the region enhances innovation and access to advanced treatment options.

The region has a great regulatory framework supporting the entry of various innovative solutions. Several companies are initiating new clinical trials. For instance, in December 2023, The U.S. Food and Drug Administration (FDA) accepted the filing of Vanda Pharmaceuticals Inc.'s New Drug Application (NDA) for tradipitant for the treatment of symptoms of gastroparesis.

In April 2022, Processa Pharmaceuticals, Inc. announced that it enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis. The above factors are expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the gastric motility disorder drugs market include Pfizer Inc., Eisai Co., Ltd., Mallinckrodt, Salvus Pharma, Atmo Biosciences, AdvaCare Pharma, Avenacy, VAIKUNTH CHEMICALS PVT. LTD., Healthy Inc and Bhumi Pharmaceuticals among others.

Key Developments

• In March 2024, Renexxion Ireland Limited announced that the U.S. Food and Drug Administration (FDA) has granted clearance for their Investigational New Drug (IND) application for naronapride. This drug is intended to treat patients suffering from gastroparesis, a condition characterized by delayed gastric emptying.
• In September 2023, Aclipse Therapeutics and its subsidiary, Aclipse Two, Inc., announced the signing of an exclusive licensing agreement with Chong Kun Dang Pharmaceutical Corporation (CKD), based in Seoul, South Korea. This agreement grants Aclipse the worldwide rights (excluding South Korea, Indonesia, and Vietnam) to develop CKD's lobeglitazone for the treatment of gastroparesis and other potential indications.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Gastric Motility Disorder Drugs Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Type
• 3.2. Snippet by Disorder Type
• 3.3. Snippet by Distribution Channel
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Gastric Motility Disorders
  • 4.1.2. Restraints
    • 4.1.2.1. Limited Drugs for Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Drug Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 6.1.2. Market Attractiveness Index, By Drug Type
• 6.2. Prokinetic Agents*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Parasympathomimetics
• 6.4. Opioid Antagonists
• 6.5. Antidiarrheals
• 6.6. Anti-Emetic Drugs
• 6.7. Antibiotics
• 6.8. Others

7. By Disorder Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 7.1.2. Market Attractiveness Index, By Disorder Type
• 7.2. Achalasia*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Esophageal spasms
• 7.4. Heartburn or Gastroesophageal Reflux Disease (GERD)
• 7.5. Gastroparesis
• 7.6. Irritable Bowel Syndrome (IBS)
• 7.7. Fecal incontinence
• 7.8. Intestinal Pseudo-obstruction
• 7.9. Others

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Hospital Pharmacies*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disorder Type
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

Key Market Players

• 11.1. Pfizer Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue's
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Eisai Co., Ltd.
• 11.3. Mallinckrodt
• 11.4. Salvus Pharma
• 11.5. Atmo Biosciences
• 11.6. AdvaCare Pharma
• 11.7. Avenacy
• 11.8. VAIKUNTH CHEMICALS PVT. LTD.
• 11.9. Healthy Inc
• 11.10. Bhumi Pharmaceuticals
• Similar data will be provided for each market player.

Emerging Market Players

• 11.11. Processa Pharmaceuticals, Inc.*
  • 11.11.1. Pipeline Products Description
  • 11.11.2. Product Key Performance Indicators (KPIs)
  • 11.11.3. Key Activities
  • 11.11.4. Market Entry Timelines
  • 11.11.5. Product Penetration Rate
  • 11.11.6. Sales Estimation and Projections
• 11.12. Vanda Pharmaceuticals Inc.
• 11.13. Renexxion Ireland Limited
• 11.14. Aclipse Therapeutics
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us